IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

Sun, Hong; Saeedi, Pouya; Karuranga, Suvi; Pinkepank, Moritz; Ogurtsova, Katherine; Duncan, Bruce Bartholow; Stein, Caroline; Basit, Abdul; Chan, Juliana C.N.; Mbanya, Jean Claude; Pavkov, Meda E.; Ramachandaran, Ambady; Wild, Sarah H.; James, Steven; Herman, William H.; Zhang, Ping; Bommer, Christian; Kuo, Shihchen; Boyko, Edward J.; Magliano, Dianna J.

doi:10.1016/j.diabres.2021.109119

Cited by 4,307 publications

(3,289 citation statements)

References 14 publications

Supporting

Mentioning

2,469

Contrasting

Unclassified

Order By: Relevance

“…Diabetes represents a worldwide epidemic with high economic and social costs. Its burden is increasing, with an estimated prevalence among adults rising from 151 million in 2000 to 536.6 million in 2021 with a prevalence of 10.5% for adults aged 20 to 79 years [ 1 ]. Furthermore, the global burden of diabetes among elderly patients is expected to increase in the coming years due to the reduced physical activity related to type 2 diabetes mellitus, unhealthy diets, rising incidences of type 1 diabetes, and aging of the world population [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, the global burden of diabetes among elderly patients is expected to increase in the coming years due to the reduced physical activity related to type 2 diabetes mellitus, unhealthy diets, rising incidences of type 1 diabetes, and aging of the world population [ 2 ]. Currently, 136 million of people aged 65 years and older have diabetes worldwide [ 1 ]. It is estimated that the number of people aged 65 years or older with diabetes will reach 195.2 million by 2030, and 276.2 million by 2045 [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry

et al. 2022

View full text Add to dashboard Cite

Background: Currently, diabetes represents the seventh leading cause of death worldwide, with a significant economic burden. The number and severity of comorbidities increase with age, and are identified as important determinants that influence the prognosis. We aimed to investigate comorbidities and outcomes in a cohort of hospitalized elderly patients affected by diabetes. Methods: In this observational study, we retrospectively analyzed data collected from the REgistro dei pazienti per lo studio delle POlipatologie e politerapie in reparti della rete Simi (RePoSI) registry. Socio-demographic, clinical characteristics, and laboratory findings were considered. The association between variables and in-hospital and 1-year follow-up were analyzed. Results: Among 4708 in-patients, 1378 (29.3%) had a diagnosis of diabetes. Patients with diabetes had more previous hospitalization, a clinically significant disability, and more need for a urinary catheter in comparison with subjects without diabetes. Patients affected by diabetes took more drugs, both at admission, at in-hospital stay, at discharge, and at 1-year follow-up. Thirty-five comorbidities were more frequent in patients with diabetes, and the first five were hypertension (57.1%), ischemic heart disease (31.4%), chronic renal failure (28.8%), atrial fibrillation (25.6%), and chronic obstructive pulmonary disease (22.7%). Heart rate was an independent predictor of in-hospital mortality. At 1-year follow-up, cancer and male sex were strongly independently associated with mortality. Conclusions: Our findings showed the severity of the impact of diabetes and its comorbidities in the real life of internal medicine and geriatric wards, and provide data to be used for a better tailored management of elderly in-patients with diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A significant portion of the world’s population is affected by diabetes mellitus (DM). Studies estimate that 8.8% of those between the ages of 20–79 in the world’s population are diabetic [ 2 ]. According to an International Diabetes Federation (IDF) report [ 2 ], the Federated States of Micronesia (Micronesia) have the world’s most overweight population, with a 30% obesity prevalence [ 3 ].…”

Section: Epidemiologymentioning

confidence: 99%

“…Studies estimate that 8.8% of those between the ages of 20–79 in the world’s population are diabetic [ 2 ]. According to an International Diabetes Federation (IDF) report [ 2 ], the Federated States of Micronesia (Micronesia) have the world’s most overweight population, with a 30% obesity prevalence [ 3 ]. On the other hand, North American and Caribbean adults aged between 20–79 years have the highest prevalence (13%) of diabetes among Western IDF regions [ 2 ].…”

Section: Epidemiologymentioning

confidence: 99%

“…According to an International Diabetes Federation (IDF) report [ 2 ], the Federated States of Micronesia (Micronesia) have the world’s most overweight population, with a 30% obesity prevalence [ 3 ]. On the other hand, North American and Caribbean adults aged between 20–79 years have the highest prevalence (13%) of diabetes among Western IDF regions [ 2 ]. In South Asian countries, diabetes prevalence is at its highest in Mauritius (22%), followed by Sri Lanka (10.7%), and India (10.4%) [ 2 ].…”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities

et al. 2022

View full text Add to dashboard Cite

There are substantial shortcomings in the drugs currently available for treatment of type 2 diabetes mellitus. The global diabetic crisis has not abated despite the introduction of new types of drugs and targets. Persistent unaddressed patient needs remain a significant factor in the quest for new leads in routine studies. Drug discovery methods in this area have followed developments in the market, contributing to a recent rise in the number of molecules. Nevertheless, troubling developments and fresh challenges are still evident. Recently, metformin, the most widely used first-line drug for diabetes, was found to contain a carcinogenic contaminant known as N-nitroso dimethylamine (NDMA). Therefore, purity and toxicity are also a big challenge for drug discovery and development. Moreover, newer drug classes against SGLT-2 illustrate both progress and difficulties. The same was true previously in the case of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Furthermore, researchers must study the importance of mechanistic characteristics of novel compounds, as well as exposure-related hazardous aspects of current and newly identified protein targets, in order to identify new pharmacological molecules with improved selectivity and specificity.

show abstract

Diagnosis and Management of Prediabetes

Echouffo‐Tcheugui¹,

Perreault

et al. 2023

JAMA

114

View full text Add to dashboard Cite

ImportancePrediabetes, an intermediate stage between normal glucose regulation and diabetes, affects 1 in 3 adults in the US and approximately 720 million individuals worldwide.ObservationsPrediabetes is defined by a fasting glucose level of 100 to 125 mg/dL, a glucose level of 140 to 199 mg/dL measured 2 hours after a 75-g oral glucose load, or glycated hemoglobin level (HbA1C) of 5.7% to 6.4% or 6.0% to 6.4%. In the US, approximately 10% of people with prediabetes progress to having diabetes each year. A meta-analysis found that prediabetes at baseline was associated with increased mortality and increased cardiovascular event rates (excess absolute risk, 7.36 per 10 000 person-years for mortality and 8.75 per 10 000 person-years for cardiovascular disease during 6.6 years). Intensive lifestyle modification, consisting of calorie restriction, increased physical activity (≥150 min/wk), self-monitoring, and motivational support, decreased the incidence of diabetes by 6.2 cases per 100 person-years during a 3-year period. Metformin decreased the risk of diabetes among individuals with prediabetes by 3.2 cases per 100 person-years during 3 years. Metformin is most effective for women with prior gestational diabetes and for individuals younger than 60 years with body mass index of 35 or greater, fasting plasma glucose level of 110 mg/dL or higher, or HbA1c level of 6.0% or higher.Conclusions and RelevancePrediabetes is associated with increased risk of diabetes, cardiovascular events, and mortality. First-line therapy for prediabetes is lifestyle modification that includes weight loss and exercise or metformin. Lifestyle modification is associated with a larger benefit than metformin.

show abstract

IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

Cited by 4,307 publications

References 14 publications

Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry

Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry

Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities

Diagnosis and Management of Prediabetes

Contact Info

Product

Resources

About